Présentation de l'entreprise
CDT Equity Inc. operates as a clinical-stage specialty biopharmaceutical entity focused on developing pharmaceutical products designed to address unmet medical needs within specific therapeutic areas, namely autoimmune diseases and idiopathic male infertility. The company's development pipeline currently includes the asset AZD1656, which has successfully completed Phase I trials for the treatment of type 2 diabetes, marking a significant step in its research trajectory. This organization functions within the Healthcare sector, specifically the Biotechnology industry, which is characterized by high capital requirements, long development cycles, and significant regulatory risk associated with bringing new therapies to market. As a small-cap entity, CDT Equity Inc. holds a market capitalization of $24.18 million and employs a workforce of six individuals, reflecting a lean organizational structure typical of early-stage biotechnology firms. The combination of a market cap under $25 million and zero reported annual revenue indicates that the company is in a pre-commercialization phase where value is derived from intellectual property and clinical trial progress rather than current cash flows from product sales.
Santé financière
The company reports a Net Income (TTM) of $-20,305,000 and an EBITDA of $-16,895,000, while the Revenue (TTM) figure is not available due to the lack of commercial sales. The substantial gap between the reported net income and the EBITDA figure reveals a significant impact from non-operating expenses or one-time charges, as the EBITDA loss is roughly $3.4 million lower than the net income loss. Free Cash Flow stands at $-16,540,875, which indicates that the company is burning cash rapidly to fund its R&D operations and clinical trial expenses, leaving little to no financial flexibility for external expansion or strategic acquisitions without additional capital raising. All three margin metrics are recorded at 0.0%: the Gross Margin is 0.0%, the Operating Margin is 0.0%, and the Profit Margin is 0.0%, a common characteristic for clinical-stage biotechs where revenue is negligible relative to operating expenses, rendering traditional margin analysis less meaningful at this stage of development. On the balance sheet, the company holds $3.84 million in cash against $1.88 million in debt, resulting in a Debt to Equity ratio of 43.83, which suggests a leveraged position relative to its equity base despite the absolute cash amount being positive. The Current Ratio is 1.66, indicating that the company possesses sufficient current assets to cover its short-term liabilities, providing a moderate buffer against immediate liquidity pressures. Return on Equity is listed as N/A due to the lack of positive earnings, while Return on Assets is -207.0%, a metric that highlights the significant financial drag of the asset base relative to the small equity base in the absence of profitability.
Évaluation de la valorisation
The P/E Ratio (TTM) and Forward P/E are both listed as N/A, which implies that traditional earnings-based valuation models are inapplicable given the company's lack of positive net income and the absence of forward earnings guidance. The Price to Book ratio is 0.06, a figure that suggests the company's market valuation is trading at a fraction of its book value, often seen in distressed or high-risk biotechnology assets where the market discounts future potential heavily against current tangible assets. The Price to Sales ratio is N/A and the EV/EBITDA is 0.10, where the extremely low EV/EBITDA multiple reflects the company's negative earnings and the market's pricing in of high execution risk associated with bringing a clinical-stage asset to market. The stock has experienced significant volatility, with a 52-Week High of $4200.00 and a 52-Week Low of $3.64, indicating that the current trading price sits at the extreme lower end of this historical range, specifically trading at approximately 99.91% below the 52-week high. The Beta value is 2.08, which signifies that the stock's price volatility is more than double that of the broader market, meaning the asset is highly sensitive to market fluctuations and investor sentiment regarding the biotechnology sector.
Growth & Income
Revenue Growth (YoY) and Earnings Growth (YoY) are both listed as N/A, which prevents a direct comparison of growth rates between earnings and revenue as both commercial metrics are currently absent. Consequently, the company does not pay dividends, evidenced by a Dividend Yield of N/A and a Payout Ratio of 0.0%, meaning the company reinvests all available resources and generates no income return for shareholders through distributions. Instead of generating cash flow for dividend payments, the company utilizes its cash reserves to fund ongoing clinical trials and research activities aimed at advancing its pipeline assets like AZD1656. The overall growth and income profile is characterized by a complete absence of current commercial performance and income generation, relying entirely on future potential rather than historical growth metrics or dividend income.